Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 7/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21569202 | 1.00 | HTR2B (0.47) | HTR2BMAPTMEN1KMT2ATP53 | |
| SCHEMBL21569278 | 0.91 | HTR2B (0.49) | HTR2BMAPTMEN1KMT2ANPC1 | |
| SCHEMBL21947571 | 0.91 | HTR2B (0.49) | HTR2BMAPTMEN1KMT2ANPC1 | |
| SCHEMBL21545552 | 0.90 | MAPT (0.53) | HTR2BMAPTMEN1KMT2ATP53 | |
| SCHEMBL20476887 | 0.90 | MAPT (0.53) | HTR2BMAPTMEN1KMT2ATP53 | |
| SCHEMBL21545502 | 0.89 | TP53 (0.48) | HTR2BMAPTMEN1KMT2ATP53 | |
| SCHEMBL21545505 | 0.89 | TP53 (0.48) | HTR2BMAPTMEN1KMT2ATP53 | |
| SCHEMBL21569361 | 0.88 | TP53 (0.56) | HTR2BMAPTMEN1KMT2ATP53 | |
| SCHEMBL21947462 | 0.88 | HTR2B (0.54) | HTR2BMAPTMEN1KMT2ATP53 | |
| SCHEMBL21947454 | 0.88 | MAPT (0.56) | HTR2BMAPTMEN1KMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10654837-B2 | Sulphamoylaryl derivatives and use thereof as medicaments for the treatment of liver fibrosis | JANSSEN PHARMACEUTICA NV (BE) | 2020-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10654837-B2 | Sulphamoylaryl derivatives and use thereof as medicaments for the treatment of liver fibrosis | HTR2B, HTR3B, HTR1A | HTR2B 1/4885MAPT 4615/4885MEN1 3949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.